Dark

Check out our API

ROIV
Roivant Sciences Ltd. Common Shares
stock NASDAQ

Market Open

Sep 8, 2026 10:46:07 AM EDT

40.89USD+17.063%(+5.96)7,546,030

40.85Bid 40.88Ask 0.03Spread

Pre-market

Sep 8, 2026 9:29:30 AM EDT

40.00USD+14.515%(+5.07)293,355

After-hours

Sep 4, 2026 4:00:30 PM EDT

34.93USD-0.014%(-0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 25, 2022

04:30PM EST Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at two upcoming conferences: GlobeNewswire Inc

Jan 5, 2022

04:33PM EST Roivant Sciences Reports Licensing Of Splicing Modulator Benzinga

04:30PM EST -- Roivant will develop RVT-2001 for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes -- Roivant JPM presentation scheduled for Monday, January 10, at 2:15 p.m. ET GlobeNewswire Inc

Dec 20, 2021

10:22AM EST Roivant Sciences Ltd. (ROIV) shares are gaining more than 20 percent on Monday morning, continuing a rally since the company said on December 16 that it executed its largest deployment to date with Roivant Discovery. There were no corporate announcements from the company today to impact the stock movement. RTTNews

Dec 16, 2021

10:00AM EST Virtual Reality Startup Nanome Announces Largest Deployment to Date GlobeNewswire Inc

Dec 15, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 Benzinga

06:22AM EST Goldman Sachs Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $15 Benzinga

Nov 15, 2021

11:07AM EST Earnings Scheduled For November 15, 2021 Benzinga

10:56AM EST Roivant Sciences Q2 EPS $(0.32) Misses $(0.15) Estimate, Sales $13.99M Beat $6.94M Estimate Benzinga

07:00AM EST Roivant Sciences Reports Financial Results for the Quarter Ended GlobeNewswire Inc

Nov 8, 2021

09:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 Benzinga

06:00AM EST HC Wainwright & Co. Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $14 Benzinga

Nov 1, 2021

06:35AM EDT SVB Leerink Initiates Coverage On Roivant Sciences with Outperform Rating, Announces Price Target of $11 Benzinga

Oct 26, 2021

10:30AM EDT Shares of Roivant Sciences Ltd. (ROIV) are gaining over 20% on Tuesday morning. ROIV is currently trading at $8.51, up $1.47 or 20.88%, on the Nasdaq. RTTNews

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2021 Benzinga

09:23AM EDT Jefferies Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $10 Benzinga

08:12AM EDT Cowen & Co. Initiates Coverage On Roivant Sciences with Outperform Rating Benzinga

07:45AM EDT Truist Securities Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $15 Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

10:11AM EDT Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q3 Views Benzinga

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Oct 1, 2021

08:00AM EDT -- Roivant will begin trading on Nasdaq under the ticker ROIV later today -- R&D Day presentations from September 28th highlighting Roivants pipeline and discovery platform available on Roivants investor page GlobeNewswire Inc

Share